As of 2026 it remains in clinical trials for obesity, type 2 diabetes, and related conditions, and it has not received FDA approval for any indication
Understanding what to expect at each phase helps maintain motivation and allows appropriate protocol adjustments
Subcutaneous injection delivers the peptide into the fatty tissue layer beneath the skin
Around 2025, he told Fortune , theres going to be a lot of people regaining their weight. And there are some clues that weight-loss companies are starting to prepare for that eventuality: In recent weeks, Noom has released a new round of Instagram advertisementsmany of them with the temporary language taken out
By working on these receptors, GLP-1RAs can influence so much more than just appetite control
The answer isn't a simple yes or no